Compare Canadian National Railway Co. (CNI) vs BIO-TECHNE Corp (TECH) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Canadian National Railway Co. vs BIO-TECHNE Corp — how do they compare? Canadian National Railway Co. trades at $126.3 (market cap $75.59B), while BIO-TECHNE Corp trades at $72.13 (market cap $11.24B). The key difference: Canadian National Railway Co. is far larger — about 6.7× BIO-TECHNE Corp's market cap, and Canadian National Railway Co. pays the higher dividend (2.08%). Which is the better fit depends on your goals.
| CNI | TECH | |
|---|---|---|
Market Cap | $75.59B | $11.24B |
Sector | Industrials | Health |
52-Week High | $130.58 | $72.29 |
52-Week Low | $90.91 | $43.31 |
Enterprise Value | $91.60B | $11.32B |
Dividend Yield | 2.08% | 0.44% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Canadian National Railway (CNI) trades at $126.60, up 0.16% with neutral technical signals. The company reported strong Q2 2026 results with EPS of $1.50 beating estimates by 7.9% and raised full-year guidance. Fundamentals show solid profitability with 26.92% net margin and 22.02% ROE, though valuation appears elevated at 22.77 P/E. Recent news highlights record grain movements and over 300 customer growth projects across CN's network.
CNI presents a mixed outlook with strong operational execution offset by valuation concerns. The 20% upside to consensus price target of $152.38 offers potential, but debt levels rising to 36.61% of assets and competitive pressures warrant caution. Earnings consistency remains key with Q3 results pending.
Bio-Techne (TECH) trades at $72.29, up 0.54% today, with a bullish technical signal from moving averages and a consensus analyst price target of $71.67. Recent earnings showed mixed results, with a Q4 2025 beat but a Q1 2026 miss. The company maintains strong gross margins at 64.96% but faces declining net income margins, down to 6.01% in 2025. Positive cash flow trends and a pending acquisition by Merck highlight ongoing corporate developments.
Outlook is balanced with growth potential from product innovation and acquisition synergies, but risks include earnings volatility, high valuation multiples, and shareholder litigation over the merger terms. Institutional sentiment is split evenly between buy and hold ratings, reflecting cautious optimism amid execution challenges.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Canadian National Railway Co.
Canadian National's railway spans Canada from coast to coast and extends through Chicago to the Gulf of Mexico. In 2019, CN delivered almost 6 million carloads over its 19,600 miles of track. CN generated roughly CAD 14 billion in total revenue by hauling intermodal containers (25% of consolidated revenue), petroleum and chemicals (21%), grain and fertilizers (16%), forest products (12%), metals and mining (11%), automotive shipments (6%), and coal (4%). Other items constitute the remaining revenue.
Read more on CNI →About BIO-TECHNE Corp
Based in Minnesota, Bio-Techne is a life sciences manufacturer supplying consumables and instruments for the pharma, biotech, academic, and diagnostic markets. The company reports in two segments, protein sciences (75% of revenue), and diagnostics and genomics (25%). The protein-focused segment makes equipment and associated consumables for protein characterization and analysis and sells antibodies for research and clinical purposes. In diagnostics, Bio-Techne provides controls and calibrators for diagnostic manufacturers and has a portfolio of diagnostic oncology assays. The United States accounts for about 55% of revenue, and the firm also has operations in EMEA (20% of sales), the U.K. (5%), and APAC (15%), with the rest of the world accounting for the remaining 5%.
Read more on TECH →
